AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 FEB 13 - (NewsRx.com & NewsRx.net) -- Scientists at Cancer Research U.K. say they now have conclusive proof that tamoxifen can prevent breast cancer in healthy high-risk women.
An international team led by Professor Jack Cuzick, a scientist and senior researcher at the charity, conducted an extensive review of the drug's track record in prevention trials.
The findings, published in Lancet, showed that drug reduced the incidence of breast cancer by 38% in healthy women with a high chance of developing the disease.
Researchers said the next challenge is to minimize the side effects of tamoxifen so that it can fulfill its potential as a frontline preventative drug.
"In our analysis we combined all the available evidence from studies using tamoxifen for breast cancer prevention - collectively involving over 40,000 women - and it is clear to us now that the drug can reduce the chance of high-risk women developing the disease," said Cuzick, of the Cancer Research U.K. Epidemiology, Mathematics and Statistics Group in London.
The team, involving scientists from Australia, Italy, and the U.K., combined and reanalyzed the results of 14 trials including data on breast cancer prevention.
They examined results from four of them, involving 28,000 women that tested the role of tamoxifen as a preventive treatment. They also looked at one, involving 7,700 women, which tested the performance of the drug raloxifene. The trials compared the performance of both with a placebo.
Source: HighBeam Research, Scientists offer conclusive proof on preventive effects of tamoxifen.